Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | RRM2 | P31350 | 1/20 | 0.39 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709487 | 0.90 | CASP3 (0.46) | CASP3MMERRM1RRM2RRM2B | |
| SCHEMBL24965934 | 0.89 | CASP3 (0.35) | CASP3RRM1RRM2RRM2BREN | |
| SCHEMBL29709552 | 0.86 | CASP3 (0.43) | CASP3MDM4TP53TNFKMT2A | |
| SCHEMBL29670399 | 0.83 | MME (0.44) | CASP3MMEMDM4TP53TNF | |
| SCHEMBL30036724 | 0.80 | CASP3 (0.42) | CASP3MMERRM1RRM2RRM2B | |
| SCHEMBL24966013 | 0.78 | CASP3 (0.39) | CASP3RRM1RRM2RRM2BPTPN1 | |
| SCHEMBL24966009 | 0.78 | CASP3 (0.39) | CASP3RRM1RRM2RRM2BPTPN1 | |
| SCHEMBL22605956 | 0.78 | FPR2 (0.39) | CASP3RRM1RRM2RRM2BREN | |
| SCHEMBL22605955 | 0.78 | FPR2 (0.39) | CASP3RRM1RRM2RRM2BREN | |
| SCHEMBL29696715 | 0.77 | CASP3 (0.48) | CASP3MDM4TP53TNFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| CN-114630835-B | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4056580-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-14 | — | — | EP | disclosed |
| CN-114630835-A | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | CASP3 1864/4885MME 21/4885RRM1 3109/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | CASP3 1864/4885MME 21/4885RRM1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.